Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts.

ABSTRACT: A total of 410 patients with blast phase myeloproliferative neoplasm (MPN-BP) were retrospectively reviewed: 248 from the Mayo Clinic and 162 from Italy. Median survival was 3.6 months, with no improvement over the last 15 years. Multivariable analysis performed on the Mayo cohort identified high risk karyotype, platelet count??65 years and transfusion need as independent risk factors for survival. Also in the Mayo cohort, intensive chemotherapy resulted in complete remission (CR) or CR with incomplete count recovery (CRi) rates of 35 and 24%, respectively; treatment-specified 3-year/5-year survival rates were 32/10% for patients receiving allogeneic stem cell transplant (AlloSCT) (n?=?24), 19/13% for patients achieving CR/CRi but were not transplanted (n?=?24), and 1/1% in the absence of both AlloSCT and CR/CRi (n?=?200) (p?

SUBMITTER: Tefferi A 

PROVIDER: S-EPMC5940634 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature